Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study for patient with Philadelphia chromosome positive acute lymphoblastic leukemia to determin the role of Dasatinb combined chemotherapy and allogeneic stem cell transplantation (PHII PHD)

Next Previous
Trial Profile

Phase II study for patient with Philadelphia chromosome positive acute lymphoblastic leukemia to determin the role of Dasatinb combined chemotherapy and allogeneic stem cell transplantation (PHII PHD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms PHII PHD

Most Recent Events

  • 06 Feb 2025 Planned End Date changed from 31 Mar 2020 to 1 Dec 2027.
  • 06 Feb 2025 Planned primary completion date changed to 1 Feb 2027.
  • 02 Nov 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top